Articles > Insulins & Non-insulins

Everything you need to know this week about type 1 diabetes and coronavirus updates, in one easy-to-read place!

Everything you need to know this week about type 1 diabetes and coronavirus updates, in one easy-to-read place!

We're going to take the opportunity to share out some critical resources each week that may help people get through this challenging coronavirus pandemic with the help of partners and experts.

We're going to take the opportunity to share out some critical resources each week that may help people get through this challenging coronavirus pandemic with the help of partners and experts.

We're going to take the opportunity to share out some critical resources each week that may help people get through this challenging coronavirus pandemic with the help of partners and experts.

We're going to take the opportunity to share out some critical resources each week that may help people get through this challenging coronavirus pandemic with the help of partners and experts.

David Walton, CEO of T1D Exchange, sat down this week with Scott Benner, host of the Juicebox Podcast, to talk about their respective history with type 1 diabetes. The conversation covered a wide range of topics: Scott and Dave discussed their personal relationships with T1D, experiences in the industry, and strategies for dealing with the disease. …

Lately, we are inundated with negative reports and information surrounding the Coronavirus outbreak. Fortunately, there is some good news for people with type 1 diabetes. Eli Lilly announced that beginning April 6, 2020, and for $35.00 dollars a month regardless of having a health insurance plan or not having health insurance at all, people with …

the liver can be just as important as the pancreas in treating type 1 diabetes

Diasome Pharmaceuticals announced positive results this week from a Phase 2 study of its injectable hepatocyte directed vesicle (HDV) additive for insulin in patients with type 1 diabetes. The news could prove a major step forward for therapies that aim to improve and optimize the way insulin is used and metabolized by the body. In …

Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.